Drug recall · March 22, 2017
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg recall
Why: Failed Impurities/Degradation Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56
- Lots / codes
Lot 30227056A; Exp. 03/17
- Quantity
- 7,628 HDPE bottles (228,840 tablets)
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Nationwide
- Initiated
- February 7, 2017 · Voluntary: Firm initiated
- Classified
- March 10, 2017
- Reported
- March 22, 2017
- Ended
- February 16, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Naloxone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.